199 related articles for article (PubMed ID: 25003995)
41. Design, synthesis, and docking study of new quinoline derivatives as antitumor agents.
Nasr EE; Mostafa AS; El-Sayed MAA; Massoud MAM
Arch Pharm (Weinheim); 2019 Jul; 352(7):e1800355. PubMed ID: 31081954
[TBL] [Abstract][Full Text] [Related]
42. Synthesis, cytotoxicity and structure-activity relationship of indolizinoquinolinedione derivatives as DNA topoisomerase IB catalytic inhibitors.
Yu Q; Yang H; Zhu TW; Yu LM; Chen JW; Gu LQ; Huang ZS; An LK
Eur J Med Chem; 2018 May; 152():195-207. PubMed ID: 29705710
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors.
Dong G; Fang Y; Liu Y; Liu N; Wu S; Zhang W; Sheng C
Bioorg Med Chem Lett; 2017 May; 27(9):1929-1933. PubMed ID: 28351590
[TBL] [Abstract][Full Text] [Related]
44. RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1.
Lian C; Cao S; Zeng W; Li Y; Su J; Li J; Zhao S; Wu L; Tao J; Zhou J; Chen X; Peng C
Biochem Pharmacol; 2020 Jan; 171():113716. PubMed ID: 31751535
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and biological evaluations of novel indenoisoquinolines as topoisomerase I inhibitors.
Zhang X; Wang R; Zhao L; Lu N; Wang J; You Q; Li Z; Guo Q
Bioorg Med Chem Lett; 2012 Jan; 22(2):1276-81. PubMed ID: 22079759
[TBL] [Abstract][Full Text] [Related]
46. Synthesis, Molecular Docking and Biological Evaluation of Quinolone Derivatives as Novel Anticancer Agents.
Li J; Zheng TC; Jin Y; Xu JG; Yu JG; Lv YW
Chem Pharm Bull (Tokyo); 2018 Jan; 66(1):55-60. PubMed ID: 29118308
[TBL] [Abstract][Full Text] [Related]
47. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Pastorino F; Loi M; Sapra P; Becherini P; Cilli M; Emionite L; Ribatti D; Greenberger LM; Horak ID; Ponzoni M
Clin Cancer Res; 2010 Oct; 16(19):4809-21. PubMed ID: 20702613
[TBL] [Abstract][Full Text] [Related]
48. Design and synthesis of 4-amino-2-phenylquinazolines as novel topoisomerase I inhibitors with molecular modeling.
Le TN; Yang SH; Khadka DB; Van HT; Cho SH; Kwon Y; Lee ES; Lee KT; Cho WJ
Bioorg Med Chem; 2011 Jul; 19(14):4399-404. PubMed ID: 21684168
[TBL] [Abstract][Full Text] [Related]
49. Molecular modelling design, synthesis and cytotoxic evaluation of certain substituted 2-(3,4,5-triacetoxybenzoylamino)benzo[d]thiazole and 2-(galloylamino)benzo[d]thiazole derivatives having potential topoisomerase-I inhibitory activity.
Ismail MA; Tratrat C; Haroun MG
J Enzyme Inhib Med Chem; 2013 Dec; 28(6):1331-45. PubMed ID: 22957723
[TBL] [Abstract][Full Text] [Related]
50. Antitumor agents 294. Novel E-ring-modified camptothecin-4β-anilino-4'-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents.
Ye D; Shi Q; Leung CH; Kim SW; Park SY; Gullen EA; Jiang ZL; Zhu H; Morris-Natschke SL; Cheng YC; Lee KH
Bioorg Med Chem; 2012 Jul; 20(14):4489-94. PubMed ID: 22698783
[TBL] [Abstract][Full Text] [Related]
51. Design and one-pot synthesis of new 7-acyl camptothecin derivatives as potent cytotoxic agents.
Liu YQ; Dai W; Wang CY; Morris-Natschke SL; Zhou XW; Yang L; Yang XM; Li WQ; Lee KH
Bioorg Med Chem Lett; 2012 Dec; 22(24):7659-61. PubMed ID: 23102893
[TBL] [Abstract][Full Text] [Related]
52. Biological impact and therapeutic potential of a novel camptothecin derivative (FLQY2) in pancreatic cancer through inactivation of the PDK1/AKT/mTOR pathway.
Wang W; Xiong H; Li L; Hu X; Zhuang W; Li J; Sun X; Yu Y; Yu Y; Guo Y; Wang Y; Wang R; Wang H; Li Q
Bioorg Chem; 2024 Jul; 148():107436. PubMed ID: 38735265
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis, and biological evaluation of novel benzodiazepine derivatives as anticancer agents through inhibition of tubulin polymerization in vitro and in vivo.
Pang Y; Lin H; Ou C; Cao Y; An B; Yan J; Li X
Eur J Med Chem; 2019 Nov; 182():111670. PubMed ID: 31499359
[TBL] [Abstract][Full Text] [Related]
54. New modulated design and synthesis of quercetin-Cu(II)/Zn(II)-Sn2(IV) scaffold as anticancer agents: in vitro DNA binding profile, DNA cleavage pathway and Topo-I activity.
Tabassum S; Zaki M; Afzal M; Arjmand F
Dalton Trans; 2013 Jul; 42(27):10029-41. PubMed ID: 23715526
[TBL] [Abstract][Full Text] [Related]
55. Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors.
Yao BL; Mai YW; Chen SB; Xie HT; Yao PF; Ou TM; Tan JH; Wang HG; Li D; Huang SL; Gu LQ; Huang ZS
Eur J Med Chem; 2015 Mar; 92():540-53. PubMed ID: 25599951
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
[TBL] [Abstract][Full Text] [Related]
57. Comparative in vitro Studies of the Topoisomerase I Inhibition and Anticancer Activities of Metallated N-Confused Porphyrins and Metallated Porphyrins.
Halder N; Dzhemileva LU; Ramazanov IR; D'yakonov VA; Dzhemilev UM; Rath H
ChemMedChem; 2020 Apr; 15(7):632-642. PubMed ID: 32154640
[TBL] [Abstract][Full Text] [Related]
58. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction.
Nan X; Zhang J; Li HJ; Wu R; Fang SB; Zhang ZZ; Wu YC
Eur J Med Chem; 2020 Aug; 200():112470. PubMed ID: 32505087
[TBL] [Abstract][Full Text] [Related]
59. Design and Synthesis of Arylnaphthalene Lignan Lactone Derivatives as Potent Topoisomerase Inhibitors.
Chen W; Feng Z; Hu D; Meng J
Med Chem; 2021; 17(8):856-865. PubMed ID: 32520691
[TBL] [Abstract][Full Text] [Related]
60. Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity.
Abdel-Aziz M; Park SE; Abuo-Rahma Gel-D; Sayed MA; Kwon Y
Eur J Med Chem; 2013 Nov; 69():427-38. PubMed ID: 24090914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
